Intraarticular Steroids, Saline and Occupational Therapy in People With CMC1 Osteoarthritis
Key facts
- Phase
- Phase 4
This trial has no sites in United States.
It has sites in one country. Choose a country to see its sites.
Trial details
- Who runs it
- Diakonhjemmet Hospital
- Trial code
- NCT06084364
- Record updated
- 2 November 2026
- Original description
A placebo-controlled randomized controlled trial exploring the effect of intraarticular steroids, saline or an occupational therapy intervention in inflammatory carpometacarpal-1 osteoarthritisRead full original descriptionShow less
Painful Inflammatory Carpometacarpal-1 Osteoarthritis Treated With Intraarticular Steroids, Saline or an Occupational Therapy Intervention: the PICASSO Trial.
A placebo-controlled randomized controlled trial exploring the effect of intraarticular steroids, saline or an occupational therapy intervention in inflammatory carpometacarpal-1 osteoarthritis
Inclusion: Adult (40-85 years of age) men and women; In target CMC-1 joint:; OA confirmed by radiographs or ultrasound examination, and; Inflammation by ultrasound (grey scale synovitis grade 1-3), and; Pain of at least 3 on a 0-10 Numeric Rating Scale (NRS) at rest or during activities at both pre-screening and screening; Patient is assessed as eligible for the proposed use of Kenacort-T.
Exclusion: More than 3 previous IACS in the target CMC-1 joint; Use of oral, intramuscular or intravenous steroids in the last 12 weeks; Previous surgery of the target CMC-1 joint; Planned hand surgery in the coming 24 weeks; Systemic inflammatory joint diseases (such as rheumatoid arthritis (RA), psoriatic arthritis or gout) or other conditions that can better explain the hand pain (such as thoracic outlet syndrome, carpal tunnel disease, diabetic cheiropathy, hand injury in previous six months, or palmar tenosynovitis/trigger finger); Patients vaccinated or immunized with live virus vaccines in the last 2 weeks; Infection, skin disease or wounds at joint injection site; Serious comorbidities, cognitive dysfunction, substance/alcohol abuse or any other medical condition that makes adherence to the study protocol difficult; Severe or uncontrolled infections; Any condition that in the view of the investigator would suggest that the patient is unable to comply with the study protocol and procedures; Known hypersensitivity to Triamcinolone acetonide (Kenacort) or any of the excipients (sodium carboxymethylcellulose, sodium chloride, polysorbate, benzyl alcohol, sodium hydroxide or hydrochloric acid); Use of thumb orthosis on most of the days or structured hand exercises in the last 12 weeks; Intraarticular injections in the target CMC-1 joint in the last 12 weeks; Do not want to quit using oral or topical NSAIDs on the hands (such as ibuprofen, diclofenac, etoricoxib, naproxen) in the next 12 weeks; Diagnosis of fibromyalgia; Diagnosis of psoriasis; Included in another clinical study; Use of digitalis glycosides; Not being able to talk or understand Norwegian; Known pregnancy or planned pregnancy in the next 6 months.